Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CryoCath Technologies, Inc.
Freezor MAX obtains FDA approval in the U.S.
December 7th, 2004
CryoCath Technologies, Inc., announced that its Freezor MAX catheter device has received premarket application supplement approval from the U.S. Food and Drug Administration (FDA), allowing the company to launch its fifth product into the U.S. Freezor MAX is indicated for minimally invasive cardiac surgery procedures, including the treatment of cardiac arrhythmias. "By providing another best-in-class device in the hands of our target physician base, we are delivering on our commitment to become the dominant player in the field of cardiac ablation," said Steve Arless, president and CEO of CryoCath. "Already a very successful product for us in Europe,...
Source: Cardiovascular Business Week (2004-12-07)
|
